Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops

Overview

This study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.

Full Title of Study: “Subjective Patient Assessment Comparing Overall Tolerability and Satisfaction of a Prostaglandin Analogue Including Either Bimatoprost 0.01% or Latanoprost.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: September 2014

Detailed Description

Patients enrolled in this study completed a validated survey instrument (COMTOL) examining tolerability of topically applied ophthalmic medications that they are already taking in their regular course of care for glaucoma. The purpose of the study is to determine whether side effects and symptoms of the drugs already being taken cause problems with activities of daily living.

Arms, Groups and Cohorts

  • bimatoprost
    • These patients take bimatoprost topically for glaucoma.
  • latanoprost group
    • These patients take latanoprost topically for glaucoma.

Clinical Trial Outcome Measures

Primary Measures

  • Tolerability of Medications as Measured by the COMTOL Validated Instrument
    • Time Frame: at the time of enrollment in the clinic, patients will immediately complete the questionnaire and exit the study
    • Patients who are already taking the medications of interest will be enrolled from a general ophthalmology practice. Immediately after consenting to participate, they will complete a validated survey instrument called the Comparison of Ophthalmic Medication for Primary Outcome Measure Tolerability (COMTOL) questionnaire (Ophthalmology 1997; : 104:334-342). Because this study will not be a crossover trial design, and patients will only continue taking the medications they were prescribed in the course of their glaucoma therapy, the modified version will eliminate questions in the COMTOL related to subjective comparison of two medications and instead focus on tolerability of the single medication being taken by test subjects.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with glaucoma taking either bimatoprost or latanoprost Exclusion Criteria:

  • patients taking other medication or with other causes for ocular surface symptoms

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • MDbackline, LLC
  • Collaborator
    • Allergan
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • John A. Hovanesian, MD, Principal Investigator, UCLA Jules Stein Eye Institute
    • Savak Teymoorian, MD, Principal Investigator, Harvard Eye Associates

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.